Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«1234567»
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Journal:  Cabenuva: A breakthrough in HIV/AIDS treatment. (Pubmed Central) -  Mar 24, 2023   
    Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). No abstract available
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Journal:  Single center experience evaluating and initiating people with HIV on long-acting cabotegravir/rilpivirine. (Pubmed Central) -  Feb 27, 2023   
    Despite novel challenges over half of our cohort initiated LAI CAB/RPV. Evaluating for potential non-nucleoside reverse transcriptase inhibitor resistance is an important part of the workup for LAI CAB/RPV and proviral DNA resistance testing can be an additional tool to identify potential resistance.
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Enrollment open:  CAPRI: A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA (clinicaltrials.gov) -  Feb 17, 2023   
    P3,  N=12, Recruiting, 
    Evaluating for potential non-nucleoside reverse transcriptase inhibitor resistance is an important part of the workup for LAI CAB/RPV and proviral DNA resistance testing can be an additional tool to identify potential resistance. Not yet recruiting --> Recruiting
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Trial completion:  Cabenuva Injection Tracking in CHORUS (clinicaltrials.gov) -  Feb 15, 2023   
    P=N/A,  N=37, Completed, 
    Not yet recruiting --> Recruiting Enrolling by invitation --> Completed
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Enrollment open:  IMPALA: Improving HIV-1 Control in Africa With Long Acting Antiretrovirals (clinicaltrials.gov) -  Feb 3, 2023   
    P3b,  N=540, Recruiting, 
    One in ten treatment na Not yet recruiting --> Recruiting
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Adherence:  I-TRAINS: Improving Treatment and Retention Adherence in Nontraditional Settings (clinicaltrials.gov) -  Dec 28, 2022   
    P=N/A,  N=25, Active, not recruiting, 
    A major factor associated with SWI was provider comfort with safety data, reinforcing the role of continued training regarding an SWI approach. Enrolling by invitation --> Active, not recruiting | N=60 --> 25 | Trial completion date: Dec 2022 --> Jun 2023 | Trial primary completion date: Dec 2022 --> Jun 2023
  • ||||||||||  Vocabria (cabotegravir oral) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Trial completion date, Head-to-Head:  SOLAR: A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY (clinicaltrials.gov) -  Oct 26, 2022   
    P3,  N=688, Active, not recruiting, 
    Enrolling by invitation --> Active, not recruiting | N=60 --> 25 | Trial completion date: Dec 2022 --> Jun 2023 | Trial primary completion date: Dec 2022 --> Jun 2023 Trial completion date: Jul 2023 --> Mar 2023
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Trial completion date, Trial primary completion date:  Implementing Cabenuva in Arkansas HIV Programs (clinicaltrials.gov) -  Oct 24, 2022   
    P=N/A,  N=100, Recruiting, 
    Trial completion date: Jul 2023 --> Mar 2023 Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Mar 2023 --> Dec 2023
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Journal:  Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection. (Pubmed Central) -  Oct 9, 2022   
    Cabotegravir + rilpivirine long-acting provides added value  contribution to human immunodeficiency virus-1 management in Spain  compared to daily oral single-tablet regimens. Patient Reported Outcomes and  therapeutic benefit of cabotegravir + rilpivirine long-acting were highly valued  by experts, as the expected benefit in adherence and stigma-related issues  would improve overall quality of life for people living with human  immunodeficiency virus-1.
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Journal:  Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South. (Pubmed Central) -  Sep 24, 2022   
    Implementing LAI-ART at a Southern US Ryan White-funded clinic has been challenged by the following: substantial human resource capital to attain drug, administer injections, and support enrolled patients; delayed therapy initiation due to insurance denials; patient ineligibility primarily due to possible RPV resistance; and inability to provide drug regardless of payor source. These barriers may perpetuate disparities in ART access and outcomes among PWH and should be urgently addressed so that LAI-ART can be offered equitably.
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Trial completion date:  GLACIER: Study Using CABENUVA (clinicaltrials.gov) -  Sep 22, 2022   
    P4,  N=120, Recruiting, 
    These barriers may perpetuate disparities in ART access and outcomes among PWH and should be urgently addressed so that LAI-ART can be offered equitably. Trial completion date: Jul 2023 --> Jan 2024
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2-Months Is Cost Effective for the Treatment of HIV-1 in Spain (In-person; Virtual) -  Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1701;    
    Sequence data from this article have been deposited in GenBank under accession numbers: GU906860, GU906864, GU906871-GU906874, JQ305750-JQ305791, KC409134-KC409222, KM057341-KM057362, KM283892-KM284490, KT340108-KT340205, MZ468643-MZ468894, MZ671788-MZ671823, OP298017-OP302727. From the Spanish NHS perspective, CAB+RPV LA Q2M is a cost-effective alternative versus STR daily oral ART, associated with small QALY gains but also with small incremental costs increase.